Subscribe To
Eledon pharmaceuticals to present data from ongoing phase 1b trial of tegoprubart in patients undergoing kidney transplantation at the american society of nephrology kidney week 2023 annual meeting
IRVINE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company will pr...
October 13, 2023, 11:00 am
Eledon pharmaceuticals announces first participant dosed in phase 2 bestow trial evaluating tegoprubart for the prevention of rejection in kidney transplantation
Trial to assess potential of tegoprubart-based immunosuppression to improve graft function compared to ...
September 5, 2023, 11:00 am
Eledon reports data from ongoing phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation at world congress of nephrology
Results from three participants demonstrated no incidence of acute rejection at durations of 56, 154, and 232 days Strong graft function observed in a...
March 31, 2023, 10:00 am